Comments on: DARZALEX® (daratumumab) subcutaneous formulation shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smouldering multiple myeloma

Comments on: DARZALEX® (daratumumab) subcutaneous formulation shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smouldering multiple myeloma https://insideout.vn/darzalex-daratumumab-subcutaneous-formulation-shows-51-percent-reduction-in-risk-of-progression-to-active-multiple-myeloma-for-patients-with-high-risk-smouldering-multiple-myeloma/ Inside Out Sun, 08 Dec 2024 19:31:44 +0000 hourly 1 https://wordpress.org/?v=6.7.1